Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Flexi Cap Fund median (47 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Apr 2006 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | UTI - Flexi Cap Fund. |
|---|---|
| 03 Apr 2006 | ₹100.00 |
| 14 Dec 2007 | ₹129.19 |
| 26 Aug 2009 | ₹110.34 |
| 08 May 2011 | ₹145.06 |
| 17 Jan 2013 | ₹170.14 |
| 30 Sep 2014 | ₹235.10 |
| 11 Jun 2016 | ₹252.26 |
| 21 Feb 2018 | ₹293.10 |
| 04 Nov 2019 | ₹320.12 |
| 16 Jul 2021 | ₹504.27 |
| 28 Mar 2023 | ₹433.12 |
| 08 Dec 2024 | ₹658.48 |
| 20 Aug 2026 | ₹671.85 |
| Metric | UTI · Regular · IDCW NAV ₹220.97 Very High risk ★★★☆☆ | Category median Flexi Cap Fund · 47 funds |
|---|---|---|
| +1.80% | +1.86% | |
| +10.20% | +11.07% | |
| +5.63% | +8.68% | |
| +9.79% | +5.89% | |
| +9.80% | +10.09% | |
| +8.06% | — | |
| +11.54% | +13.05% | |
| +11.52% | +11.30% | |
| +11.28% | +6.14% | |
| Risk | ||
| 12.89% | 14.74% | |
| 0.29 | 0.29 | |
| 0.40 | 0.39 | |
| -52.43% | -33.63% | |
| Nifty 500 | — | |
| -1.26% | -0.84% | |
| 0.87 | 0.98 | |
| 85.0% | 96.3% | |
| 87.3% | 102.5% | |
| 1.67% | 2.15% | |
| ₹22,328Cr | ₹3,777Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 10% | 37% | |
| Kamal Gada | — | |
| 03 Apr 2006 | — | |
| 56 | — | |
| 44.4% | — | |
| 2.7% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.